Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AML
Antimicrobial Agents and Chemotherapy · 03.06.2026 · 70 (6)
DOI: 10.1128/aac.01951-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 03.06.2026. Verfasst von Carolin S Joisten und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department I of Internal Medicine, Center for Integrated Oncology (CIO), Medical Faculty and University Hospital of Cologne, University of Cologne, C…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Staurosporine, fms-Like Tyrosine Kinase 3, Triazoles. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Faculty of the University Hospital of Cologne.
Abstract (Originalsprache)
To determine midostaurin and posaconazole plasma concentrations and investigate adverse events (AEs) resembling drug-drug interactions (DDI) when both drugs were administered concomitantly during induction chemotherapy for acute myeloid leukemia (AML). Patients with FLT3-mutated AML who received midostaurin and posaconazole concomitantly between May 2019 and December 2022 were included and followed up to March 2023. Twice-weekly trough levels for midostaurin and posaconazole were measured with validated liquid chromatography–tandem mass spectrometry methods. Potential DDIs were independently reviewed by two physicians and attributed using the Drug Interaction Probability Scale (DIPS). Population pharmacokinetics analysis was done via nonlinear mixed-effect modeling. In 29 patients, concentrations ranged from 0.6 to 24.5 mg/L for midostaurin and from
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department I of Internal Medicine, Center for Integrated Oncology (CIO), Medical Faculty and University Hospital of Cologne, University of Cologne, Cologne, Germany.
- Faculty of Medicine and University Hospital Cologne, Institute of Translational Research, University of Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Ger…
- German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
- TDM Laboratory, Center for Laboratory Diagnostics, University Hospital of Cologne, Cologne, Germany.
- Department I of Internal Medicine, Division of Clinical Immunology, Medical Faculty and University Hospital of Cologne, University of Cologne, Cologne, Germany.
- Clinical Trials Center Cologne (ZKS Köln), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
ORCID-Profile: Carolin S Joisten, Sibylle C Mellinghoff, Danila Seidel, Carsten Müller, Charlotte Müller-Ohrem, Lukas P Frenzel, Florian Simon, Michael Hallek, Philipp Koehler, Oliver A Cornely, Jannik Stemler
Förderung
- Medical Faculty of the University Hospital of Cologne
Zitieren
APA
Joisten, C. S., Mellinghoff, S. C., Seidel, D., Müller, C., Müller-Ohrem, C., Kreuzer, K. A., Frenzel, L. P., Simon, F., Hallek, M., Koehler, P., Cornely, O. A., & Stemler, J. (2026). Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AML. Antimicrobial Agents and Chemotherapy, 70(6). https://doi.org/10.1128/aac.01951-25
Vancouver
Joisten CS, Mellinghoff SC, Seidel D, Müller C, Müller-Ohrem C, Kreuzer KA, et al. Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AML. Antimicrobial Agents and Chemotherapy. 2026;70(6). doi:10.1128/aac.01951-25
BibTeX
@article{Joisten2026,
author = {Joisten, Carolin S and Mellinghoff, Sibylle C and Seidel, Danila and Müller, Carsten and Müller-Ohrem, Charlotte and Kreuzer, Karl-Anton and Frenzel, Lukas P and Simon, Florian and Hallek, Michael and Koehler, Philipp and Cornely, Oliver A and Stemler, Jannik},
title = {Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AML},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {6},
doi = {10.1128/aac.01951-25}
}
EUVIMED